Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial

Todd, J. J., Lawal, T. A., Chrismer, I. C., Kokkinis, A., Grunseich, C., Jain, M. S., Waite, M. R., Biancavilla, V., Pocock, S., Brooks, K., Mendoza, C. J., Norato, G., Cheung, K., Riekhof, W., Varma, P., Colina-Prisco, C., Emile-Backer, M., Meilleur, K. G., Marks, A. R., … Mohassel, P. (2024). Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial. EClinicalMedicine, 68, 102433. https://doi.org/10.1016/j.eclinm.2024.102433
Authors:
Joshua J Todd
Tokunbor A Lawal
Irene C Chrismer
Angela Kokkinis
Christopher Grunseich
Minal S Jain
Melissa R Waite
Victoria Biancavilla
Shavonne Pocock
Kia Brooks
Christopher J Mendoza
Gina Norato
Ken Cheung
Willa Riekhof
Pooja Varma
Claudia Colina-Prisco
Magalie Emile-Backer
Katherine G Meilleur
Andrew R Marks
Yael Webb
Eugene E Marcantonio
A Reghan Foley
Carsten G Bönnemann
Payam Mohassel
Affiliated Authors:
Ken Cheung
Andrew R Marks
Author Keywords:
central core disease
congenital myopathies
Publication Type:
Article
Unique ID:
10.1016/j.eclinm.2024.102433
PMID:
Publication Date:
Data Source:
PubMed

Record Created: